Ewa Piotrowska

List of Publications by Year
in descending order

29	1,075	361045 20	454577 30
papers	citations	h-index	g-index

31	31	31	1615
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses. European Journal of Human Genetics, 2006, 14, 846-852.	1.4	161
2	Genistein-mediated inhibition of glycosaminoglycan synthesis, which corrects storage in cells of patients suffering from mucopolysaccharidoses, acts by influencing an epidermal growth factor-dependent pathway. Journal of Biomedical Science, 2009, 16, 26.	2.6	102
3	Genistin-rich soy isoflavone extract in substrate reduction therapy for Sanfilippo syndrome: An open-label, pilot study in 10 pediatric patients. Current Therapeutic Research, 2008, 69, 166-179.	0.5	92
4	Autophagy stimulation as a promising approach in treatment of neurodegenerative diseases. Metabolic Brain Disease, 2018, 33, 989-1008.	1.4	65
5	Genistein: a natural isoflavone with a potential for treatment of genetic diseases. Biochemical Society Transactions, 2010, 38, 695-701.	1.6	54
6	How close are we to therapies for Sanfilippo disease?. Metabolic Brain Disease, 2018, 33, 1-10.	1.4	52
7	Two-year follow-up of Sanfilippo Disease patients treated with a genistein-rich isoflavone extract: Assessment of effects on cognitive functions and general status of patients. Medical Science Monitor, 2011, 17, CR196-CR202.	0.5	51
8	Why are behaviors of children suffering from various neuronopathic types of mucopolysaccharidoses different?. Medical Hypotheses, 2010, 75, 605-609.	0.8	48
9	Improvement in the range of joint motion in seven patients with mucopolysaccharidosis type II during experimental gene expressionâ€targeted isoflavone therapy (GET IT). American Journal of Medical Genetics, Part A, 2011, 155, 2257-2262.	0.7	46
10	Female Fabry disease patients and X-chromosome inactivation. Gene, 2018, 641, 259-264.	1.0	44
11	Correlation between severity of mucopolysaccharidoses and combination of the residual enzyme activity and efficiency of glycosaminoglycan synthesis. Acta Paediatrica, International Journal of Paediatrics, 2009, 98, 743-749.	0.7	38
12	Autoantibodies to heat shock proteins 60, 70, and 90 in patients with rheumatoid arthritis. Cell Stress and Chaperones, 2019, 24, 283-287.	1.2	34
13	Glycosaminoglycans and mucopolysaccharidosis type III. Frontiers in Bioscience - Landmark, 2016, 21, 1393-1409.	3.0	32
14	Substrate Reduction Therapies for Mucopolysaccharidoses. Current Pharmaceutical Biotechnology, 2011, 12, 1860-1865.	0.9	26
15	Molecular analysis of mucopolysaccharidosis type VI in Poland, Belarus, Lithuania and Estonia. Molecular Genetics and Metabolism, 2012, 105, 237-243.	0.5	26
16	The Role of Dimethyl Sulfoxide (DMSO) in Gene Expression Modulation and Glycosaminoglycan Metabolism in Lysosomal Storage Disorders on an Example of Mucopolysaccharidosis. International Journal of Molecular Sciences, 2019, 20, 304.	1.8	26
17	Abnormalities in the hair morphology of patients with some but not all types of mucopolysaccharidoses. European Journal of Pediatrics, 2008, 167, 203-209.	1.3	23
18	Mucopolysaccharidosis Type VI (Maroteauxâ€“Lamy syndrome) with a predominantly cardiac phenotype. Molecular Genetics and Metabolism, 2011, 104, 695-699.	0.5	23

#	Article	IF	Citations
19	Rapid deterioration of a patient with mucopolysaccharidosis type I during interruption of enzyme replacement therapy. American Journal of Medical Genetics, Part A, 2007, 143A, 1925-1927.	0.7	21
20	Different amounts of isoflavones in various commercially available soy extracts in the light of gene expressionâ€targeted isoflavone therapy. Phytotherapy Research, 2010, 24, S109-13.	2.8	21
21	Mucopolysaccharidosis type VI: A predominantly cardiac phenotype associated with homozygosity for p.R152W mutation in the ARSB gene. American Journal of Medical Genetics, Part A, 2013, 161, 1291-1299.	0.7	16
22	Effects of flavonoids on expression of genes involved in cell cycle regulation and DNA replication in human fibroblasts. Molecular and Cellular Biochemistry, 2015, 407, 97-109.	1.4	15
23	Changes in expressions of genes involved in the regulation of cellular processes in mucopolysaccharidoses as assessed by fibroblast culture-based transcriptomic analyses. Metabolic Brain Disease, 2020, 35, 1353-1360.	1.4	13
24	Vitamin D status in patients with rheumatoid arthritis: a correlation analysis with disease activity and progression, as well as serum IL-6 levels. Acta Biochimica Polonica, 2017, 64, 667-670.	0.3	12
25	Atypical microbial infections of digestive tract may contribute to diarrhea in mucopolysaccharidosis patients: a MPS I case study. BMC Pediatrics, 2005, 5, 9.	0.7	9
26	Inhibition of Shiga toxin-converting bacteriophage development by novel antioxidant compounds. Journal of Enzyme Inhibition and Medicinal Chemistry, 2018, 33, 639-650.	2.5	8
27	Dosage Compensation in Females with X-Linked Metabolic Disorders. International Journal of Molecular Sciences, 2021, 22, 4514.	1.8	8
28	Differential effects of various soy isoflavone dietary supplements (nutraceuticals) on bacterial growth and human fibroblast viability. Acta Biochimica Polonica, 2018, 65, 325-332.	0.3	3
29	Assessment of dietary habits and lifestyle among people with HIV. Advances in Clinical and Experimental Medicine, 2020, 29, 1459-1467.	0.6	3